These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11471759)

  • 21. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
    Kampman MT; Steffensen LH
    Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
    [No Abstract]   [Full Text] [Related]  

  • 23. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemporary immunomodulatory therapy for multiple sclerosis.
    Rudick RA
    J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.
    Amato MP
    Expert Opin Pharmacother; 2004 Oct; 5(10):2115-26. PubMed ID: 15461547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
    Confavreux C; Vukusic S
    Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
    [No Abstract]   [Full Text] [Related]  

  • 28. International consensus statement on the use of disease-modifying agents in multiple sclerosis.
    Freedman MS; Blumhardt LD; Brochet B; Comi G; Noseworthy JH; Sandberg-Wollheim M; Soelberg SP;
    Mult Scler; 2002 Feb; 8(1):19-23. PubMed ID: 11936483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multiple sclerosis].
    Itoyama Y
    No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
    [No Abstract]   [Full Text] [Related]  

  • 30. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapies in neurologic disorders.
    Graves D; Vernino S
    Med Clin North Am; 2012 May; 96(3):497-523, x. PubMed ID: 22703853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomic considerations in the treatment of multiple sclerosis.
    Sharac J; McCrone P; Sabes-Figuera R
    Drugs; 2010 Sep; 70(13):1677-91. PubMed ID: 20731475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
    Pender MP; Wolfe NP
    Intern Med J; 2002 Nov; 32(11):554-63. PubMed ID: 12412939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
    Zavalishin IA; Zhuchenko TD; Peresedova AV
    Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease modifying treatment in multiple sclerosis.
    Fuller GN; Bone I
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract]   [Full Text] [Related]  

  • 38. Glatiramer acetate for the treatment of multiple sclerosis.
    Wolinsky JS
    Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 40. [Recent therapeutic strategy for multiple sclerosis].
    Itoyama Y
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1214-7. PubMed ID: 12235841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.